Cancer associated venous thromboembolism (CAT) has a high risk of recurrence and treatment-emergent bleeding [1–4]. The identification of risk factors for venous thromboembolic (VTE) recurrence and bleeding would help clinicians to tailor the anticoagulant treatment in this setting. More specifically, the availability of risk factor-based scores for VTE recurrence and the resulting identification of different risk categories could optimize the benefit-risk ratios of anticoagulant treatment [5,6].
